Skip to main content
. 2018 Mar 21;12:605–617. doi: 10.2147/DDDT.S130809

Table 4.

Treatment interruption or discontinuation and dose reduction following administration of oral rucaparib 600 mg bid

Study 10, Part 2A36
N=42
ARIEL 2, Part 124
N=204
Joint analysis (Study 10 and ARIEL 2)46
N=377
ARIEL 342
N=372
(rucaparib arm)
Discontinuation for AE (%) 10 9 10 13
Dose reduction due to AE (%) 69 39 46 55
At least one dose reduction or treatment delay (%) 90 nr 62 88

Abbreviations: AE, adverse event; N, number of patients; nr, not reported; bid, twice a day.